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Over the years, it has become clear that children growing up after neonatal critical illness
are at high risk of long-term neurocognitive deficits that impact their school performance
and daily life activities. Although the pathophysiological mechanisms remain largely
unknown, emerging evidence seems to suggest that long-term neuropsychological
deficits following neonatal critical illness are not associated with the type of treatment,
such as extracorporeal membrane oxygenation (ECMO), but rather with underlying
disease processes. In this review, neurocognitive outcome and brain pathology
following neonatal critical respiratory and cardiac illness, either treated with or
without ECMO, are described and compared in order to gain insight into potential
underlying pathophysiological mechanisms. Putting these findings together, it becomes
apparent that both children with complex congenital heart disease and children who
survived severe respiratory failure are at risk of neurocognitive deficits later in life.
Neurorehabilitation strategies, such as Cogmedworking-memory training, are discussed.
While prevention of neurocognitive deficits altogether should be strived for in the future,
this is not realistic at this moment. It is therefore of great importance that children growing
up after neonatal critical illness receive long-term care that includes psychoeducation and
personalized practical tools that can be used to improve their daily life activities.
Keywords: ECMO (extracorporeal membrane oxygenation), Newborn, respiratory failure, circulatory failure,
hippocampus
INTRODUCTION
Extracorporeal membrane oxygenation (ECMO) can be used as a lifesaving therapy in critically
ill neonates with severe refractory respiratory and/or cardiac failure. As more and more of these
patients survive to discharge (73% following respiratory illness and 42% after cardiac illness) (1),
long-term outcomes become increasingly important. It has become clear that children growing
up after neonatal critical illness are at high risk of long-term neurocognitive deficits that have a
profound impact on school performance and daily life activities (2). Survivors are at risk of ‘growing
into deficit’ as subtle brain injuries acquired at a young age only become functionally evident over
time when demands on cognitive functioning increases (3). This phenomenon is nested within
different developmental processes that occur in the brain [e.g., myelination, synaptic pruning, and
neurogenesis (4)] during the period of critical illness.
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The pathophysiological mechanisms underlying the long-
term neurodevelopmental deficits remain largely unknown.
Most likely, a complex interplay amongst different factors
associated with the underlying disease (pharmacological),
treatment and “iatrogenesis,” further complicated by the child’s
genetic predisposition (5) and social economic status (6),
determines a child’s neurodevelopment. Emerging evidence
seems to suggest that long-term neuropsychological deficits
following neonatal critical illness are not associated with the
type of treatment, such as extracorporeal membrane oxygenation
(ECMO) (7), but rather with underlying disease processes, such
as hypoxia-ischemia, stress, and neuroinflammation (2, 8, 9).
However, whether this is similar between neonates with severe
respiratory failure and neonates with cardiac anomalies remains
largely unknown. Furthermore, whether brain alterations and its
neurocognitive consequences are selective or generalized in these
patients and differs between patients treated with and without
ECMO is not yet clear.
In this review, long-term neurocognitive outcome and
brain pathology following neonatal critical respiratory and
cardiac illness, either in children treated with or without
ECMO, will be described and compared. In light of this,
potential common pathophysiological mechanisms across these
patients will be explored. Finally, suggestions to improve long-
term neurodevelopmental care, both through intervention and
counseling, will be provided.
NEURODEVELOPMENTAL OUTCOME
AFTER SEVERE RESPIRATORY FAILURE,
TREATED WITH OR WITHOUT ECMO
There are relatively few studies that have compared outcome
between ECMO and non-ECMO treated patients after severe
respiratory failure (Table 1A). In one of the first studies
comparing outcome between 7-year-old children treated
with neonatal ECMO to children treated with conventional
management (CM) in response to severe respiratory failure,
global cognitive loss, poor spatial skills, difficulties with reading
comprehension and deficits in visual and verbal memory
were found equally in both groups (12). Madderom et al.
(11) directly compared CDH survivors treated with (n = 16)
or without ECMO (n = 19) on IQ, school performance and
sustained attention at 8 years of age. Mean IQ significantly
differed between the ECMO group [91.7 (19.5)] and non-ECMO
group [111.6 (20.9)], but was normal in both groups compared
to the general population. The proportions of children with
above average, average and below average IQ did not differ
significantly between both groups (p = 0.052), but there
was a trend toward more children with below average IQ
in the ECMO group compared to the non-ECMO group. In
both groups, however, twice as many children needed extra
help in school compared to healthy peers and both groups
showed significantly impaired sustained attention compared
to healthy peers (11). The difficulties experiences in school
by these children therefore seem to be largely independent
of IQ.
Indeed, when elaborate neuropsychological assessment was
used to compare outcome between 8-year-old survivors of
congenital diaphragmatic hernia (CDH) survivors treated with
neonatal ECMO (CHD-ECMO), CDH survivors treated without
ECMO (CDH-non-ECMO) and survivors of other types of
severe respiratory failure treated with neonatal ECMO (ECMO-
other), lower IQ in the CDH-ECMO group was found compared
to the other groups. However, deficits in sustained attention
and in verbal and visuospatial memory (both immediate and
delayed recall) were found across all three groups, while other
neuropsychological outcomes were normal (9). In all groups, the
observed attention and memory problems were more severe than
expected based on their IQ, indicating specific impairments in
these domains that were independent of underlying diagnosis or
ECMO treatment (9).
Behavioral problems have been compared between neonatal
ECMO vs. non-ECMO treated survivors of respiratory failure as
well. McNally et al. (12) found an increased risk of behavioral
problems among 7-yearold children who had been treated
conventionally, in particular hyperactivity. Madderom et al.
compared self-perceived competence at 8 years of age and found
no differences between groups. Furthermore, scores were similar
to the general population. Behavioral problems did not differ
between groups either, but the groups studied were small which
makes the results less definitive (11). Future studies with large
sample sizes are needed to gain a better understanding of how
ECMOmay or may not negatively influence behavioral outcome.
In recent years, studies have assessed long-term brain
pathology and brain-function associations in these patient groups
as well. Cooper et al. (10) assessed cognitive functioning
and brain outcomes between 12-year-old survivors of acute
hypoxemic respiratory failure (AHRF) who had either received
treatment with neonatal ECMO or CM and were free of overt
neurological impairment. In both groups, a similar degree of
hippocampal atrophy was found at 12 years of age that positively
correlated with memory outcome (10). The ECMO group was
more impaired in Learning and Delayed Recognition relative to
the CM subgroup, but their total IQ was lower as well (10). These
findings thus seem to be similar to the results mentioned in the
previous paragraph (9, 11), where specific neuropsychological
deficits exist that are incongruent with their general intellectual
abilities. Furthermore, the brain alterations seem to be specific as
well. In another study, school-age survivors of neonatal ECMO
and/or CDH, hippocampal volume reductions were observed,
adjusted for total brain volume, that were associated with
worse verbal memory delayed recall. This association was found
both in children treated with and without ECMO (15). In the
same cohort, white matter microstructure was assessed, showing
alterations in the parahippocampal region of the cingulum,
a white matter tract connecting the medial temporal lobe
with the parietal and occipital lobes, to be associated with
worse visuospatial memory (15). Again, these structure-function
relationships existed in both the patients treated with andwithout
ECMO (15).
Specific long-term neurodevelopmental deficits, particularly
in memory and the hippocampus, seem to exist in survivors
of critical illness, irrespective of ECMO treatment. Nonetheless,
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TABLE 1 | Studies assessing neurocognitive outcome in ECMO vs. non-ECMO treated patients for severe respiratory failure or cardiac failure.
References Participants Assessed Methods and materials Findings
(A) SEVERE RESPIRATORY FAILURE
Cooper et al. (10) 40 children treated for acute
hypoxic respiratory failure: 27
treated with ECMO and 13 with
conventional management.
64 healthy controls
8–15 years Neuroimaging: Structural MRI
1.5 Tesla. Neurocognitive
domains: intelligence, memory
Smaller left, right and bilateral hippocampal
volume in patients. No difference in
hippocampal volume between patients treated
with ECMO and conventional treatment. The
ECMO and CM subgroups differed
consistently on Learning and Delayed
Recognition, in both of which the ECMO
subgroup scored below the CM subgroup
Leeuwen et al. (9) 65 survivors of severe respiratory
failure: 35 treated with ECMO
(CDH and other) and 30 treated
with conventional management
(CDH)
8 years Neurocognitive domains:
intelligence, attention, verbal and
visuospatial memory, executive
functioning, visuospatial
processing
Patients had average intelligence (mean
intelligence quotient ± SD, 95 ± 16), but
significantly poorer sustained attention and
memory than the norm population.
ECMO-treated CDH patients had significantly
lower mean IQ (84 ± 12) than other neonatal
ECMO patients (94 ± 10) and CDH patients
treated with conventional management (100 ±
20). Mean (SD) IQ for the ECMO
Madderom
et al. (11)
35 survivors of congenital
diaphragmatic hernia: 16 treated
with neonatal ECMO and 19 with
conventional management
8 years Neurocognitive domains:
Intelligence, concentration and
attention
Mean (SD) IQ for the ECMO group was 91.7
(19.5) vs. 111.6 (20.9) for the non-ECMO
group (p = 0.015). For all participants,
problems with concentration (68%, p < 0.001)
and with behavioral attention (33%, p = 0.021)
occurred more frequently than in reference
groups, with no difference between treatment
groups
McNally et al. (12) 90 survivors of severe respiratory
failure: 56 treated with neonatal
ECMO and 34 with conventional
management
7 years Neurocognitive domains:
Cognitive ability (verbal,
nonverbal reasoning, and spatial
abilities), number skills, spelling,
word reading, reading
comprehension and visual and
verbal memory
76% recorded a cognitive level within the
normal range. Learning problems were similar
in the 2 groups, and there were notable
difficulties with spatial and processing tasks.
Schiller et al. (13) 38 children with CDH and/or
treated with neonatal ECMO. No
controls
8–12 years Neuroimaging: Structural MRI
and DTI 3Tesla.
Neurocognitive domains:
intelligence, attention, verbal and
visuospatial memory, executive
functioning, visuospatial
processing
Mean diffusivity (MD) in the left
parahippocampal region of the cingulum
(PHC) was negatively associated with
visuospatial memory. MD in the left and right
PHC were negatively associated with verbal
memory. Bilateral hippocampal volume was
positively associated with verbal memory. No
differences between groups in the
structure-function associations found
(B) SEVERE CARDIAC FAILURE
Tindall et al. (14) 9 survivors of cardiac disease
treated with ECMO compared to
13 controls matched for cardiac
disease and age of surgery.
31 healthy controls
4–6 years Neurocognitive domains: general
cognitive ability, sustained
attention, memory, spatial
construction, verbal ability
Children treated with ECMO demonstrated
significant impairment in general cognitive
ability compared to normal controls. No group
differences were found in impulsivity or
sustained attention. On lateralized measures,
children treated with ECMO demonstrated
significant impairment in left-hand motor skill,
visual memory, and spatial construction
compared to both cardiac controls and normal
controls. There were no group differences in
general verbal ability, verbal memory,
right-hand motor skills, or tactile perception
ECMO, extracorporeal membrane oxygenation; CDH, congenital diaphragmatic hernia; CM, conventional management; MRI, magnetic resonance imaging; DTI, diffusion tensor imaging;
MRS, magnetic resonance spectroscopy.
Frontiers in Pediatrics | www.frontiersin.org 3 November 2019 | Volume 7 | Article 494
Schiller and Tibboel ECMO in Neonatal Critically Ill Children
more widespread neuropsychological impairment has also been
reported in survivors of neonatal ECMO compared to those
treated with CM (9–12). These differences may be due to more
global brain alterations as a result of greater illness severity in
the neonatal period. In line with this, in the study by Cooper
et al. (10) an increase in CSF and trend toward reduced global
white matter was observed in the ECMO group compared to the
CM group. On the contrary, although global alterations in white
matter microstructure were found in survivors of severe neonatal
respiratory failure by others as well, these were independent
of ECMO treatment (13). The explanation of this discrepancy
remains speculative, but may be because the differences are
small and are therefore difficult to detect in relatively small
study populations.
NEURODEVELOPMENTAL OUTCOME
AFTER SEVERE CARDIAC
FAILURE—TREATED WITH OR WITHOUT
ECMO
In neonates with congenital or acquired heart disease, ECMO
is used as a perioperative bridge to recovery or temporary
support. Although respiratory failure remains the most common
indication for extracorporeal life support today, the proportion
of cardiac ECMO cases has increased dramatically. ECMO has
evolved into a standard therapy for support of cardiac failure
refractory to medical care alone (16). Fortunately, this has led to
lower mortality rates in these patients and improvement of short-
term outcome (1, 16). Because of this, monitoring long-term
neurodevelopment in these patients is of great importance.
Several long-term studies have shown that neonates with
congenital or acquired heart disease are at risk of long-term
deficits in multiple neurocognitive domains, such as visuospatial
skills, executive functioning, attention and memory (17–22).
Subsequently, just as in patients with severe respiratory failure,
survivors of cardiac failure within the first weeks of life are at
increased risk of academic difficulties (17–21). Whether patients
treated with ECMO are at an even higher risk of these long-
term neurodevelopmental problems remains largely unknown.
Patients in need of ECMO obviously represent a negative case
selection due to circulatory failure post-cardiac repair. In some
patients, such as in selected patients with TGA and pulmonary
hypertension, survival is even dependent on pre-surgery support
by ECMO.
Studies comparing neurocognitive outcome after severe
cardiac failure between ECMO and non-ECMO treated patients
are very scarce (Table 1B). In an early study on this topic, Tindall
et al. (14) compared neuropsychological outcome in 4–6 year-
old children who were treated with ECMO following repair of
congenital heart defects to patients not treated with ECMO and
healthy controls. General cognitive ability was within the normal
range in both patients groups, yet significantly lower in patients
treated with ECMO when compared to healthy controls (14). On
more specific neuropsychological tasks, the ECMO group scored
significantly lower on left-hand motor skill, visual memory,
and spatial construction compared to both cardiac controls
and healthy children (14). No group differences were found in
sustained attention, general verbal ability, verbal memory, right-
hand motor skills, or tactile perception (14). Although providing
some insight into long-term neuropsychological outcome in
these patients, studies with older children are of interest as
these patients may “grow into deficit.” This phenomenon has
been described in survivors of severe respiratory failure (2), in
which early brain damage becomes only functionally evident at a
school-age due to brain maturation and increasing demands on
cognitive functioning (23, 24).
Both global and specific brain alterations have been described
in survivors of congenital heart disease (25–27). In 8–16 year-
old children with transposition of the great arteries that were
treated with the arterial switch, significant memory impairment
and abnormally small hippocampal volumes were found (20).
These impairments were similar to those described previously in
patients with acute hypoxemic respiratory failure by the same
group (10). Although the neurocognitive deficits were found
to be independent of surgical repair, no comparison was made
between patients treated with and without ECMO (20).
PATHOPHYSIOLOGICAL MECHANISMS
UNDERLYING NEURODEVELOPMENTAL
DEFICITS
Putting these findings together, it becomes apparent that
children with complex congenital heart disease and children who
survived severe respiratory failure are at risk of neurocognitive
deficits later in life. In both groups, irrespective of ECMO
treatment, these deficits lead to difficulties in school. This is
highly problematic and underscores the need to understand
the pathophysiological mechanisms underlying the long-term
neurodevelopmental deficits.
Although some studies seem to suggest that patients treated
with ECMO have worse outcomes than patients not treated
with ECMO, this is not a consistent finding (9, 11, 14). Both
global and specific brain alterations have been described in
both of these patient groups. In patients with severe respiratory
failure, these brain alterations were largely independent of
the need for ECMO treatment (13, 15). However, in a study
with school-age survivors of AHRF, patients treated with
ECMO seemed to have more widespread brain alterations
than patients not treated with ECMO (10). The question
rises what pathophysiological mechanisms are underlying
these long-term neurodevelopmental deficits. Severity of illness
and factors associated with critical illness in general have
been described to determine outcome following neonatal
critical illness (2). In addition, ECMO treatment may further
complicate neurodevelopment by affecting cerebral blood flow
and subsequently cerebral autoregulation (28). However, a
conclusive cause-effect relationship with ECMO has not been
established (28). Moreover, despite lower IQ in patients treated
with ECMO compared to patients treated without ECMO (11),
the degree of neuropsychological deficits (i.e., specific memory
and/or attention problems) and the extent to which these
interfere with daily life are similar between these two groups
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(9, 15, 29). Furthermore, in long-term imaging studies conducted
by our group, no differences in (subtle) brain abnormalities were
found either between ECMO vs. no-ECMO treated patients,
nor between patients treated with veno-arterial and venovenous
ECMO (15). These findings suggest that disease processes
other than ECMO treatment are underlying the long-term
neuropsychological deficits in these patients. An explanation for
this may be that, while studies have shown major neurologic
complications in about 20% of ECMO-treated patients (30), more
subtle brain abnormalities that cannot be detected using standard
neonatal MRI seem to be present in both ECMO and non-ECMO
patients [12, 14, 28]. While major neurologic complications
may lead to severe neurocognitive impairments such as
generally lower intellectual ability, these more subtle brain
injuries seem to be underlying the long-term neurocognitive
deficits in the memory and attention domains observed in
the survivors at school-age (29). Neuromonitoring before,
during and after neonatal ECMO treatment in these patients
is therefore of great importance. Future studies are needed in
which neuromonitoring data from near-infrared spectroscopy
(NIRS), transcranial Doppler, magnetic resonance imaging
(MRI) and/or electroencephalogram (EEG) is coupled with
neurodevelopmental outcome to see whether early predictors can
be identified.
In survivors of perinatal cardiac failure, the effect of ECMO
treatment on long-term brain alterations has, to our knowledge,
not been studied. Comparing survivors of cardiac failure to
survivors of severe respiratory failure shows both similarities
in neurodevelopmental outcome, such as memory deficits with
hippocampal alterations (10, 20), as well as differences. In
survivors of CHD, multiple neurocognitive domains, such as
visuospatial skills, executive functioning, attention and memory
(17–21), are found to be compromised. Neurodevelopmental
deficits therefore seem to be more widespread in these patient
groups than in patients with severe respiratory failure. This
may be due to the timing of brain injury. Several studies have
shown that brain alterations in patients with CHD already exist
prenatally, presumably due to lower oxygen tension in utero
(31–33). In contrast, patients with severe respiratory failure are
generally born at term and only exposed to deleterious conditions
that may affect brain development postnatally. Although
evidence from studies in patients with severe respiratory failure
seem to suggest otherwise, ECMO treatment in patients with
CHDmay lead to an even increased risk of diffuse or global brain
alterations and subsequent neuropsychological deficits due to its
potential effect on cerebral autoregulation (28). However, future
studies in CHD patients are needed to assess this notion.
Looking at similarities, we know that all patients described in
this review are at risk of hypoxia-ischemia. Evidence has shown
that white matter, in particular in the periventricular regions,
and the hippocampus are particularly susceptible to hypoxic-
ischemic insults (2, 34, 35). Using animal models, premyelinating
oligodendrocytes (pre-OLs) in cerebral white matter have been
found to be selectively targeted by oxidative stress. These cells
account for ∼90% of the total oligodendroglial population at 28
weeks of gestation and ∼50% at term (35). Increased regional
susceptibility of the periventricular white matter is suggested
to be due to the distribution of these pre-OLs and relative
underdevelopment of distal arterial fields to these areas (35, 36).
In addition, studies using animal and in vitro models have
demonstrated that the hippocampus shows more pronounced
changes following hypoxia-ischaemia than other brain structures
(34). Indeed, critically ill neonates exposed to hypoxic-ischemic
injuries, irrespective of gestatational age or underlying diseasse,
have been shown to be at increased risk of periventricular white
matter abnormalities and hipopcampal damage (2). Since white
matter is important for high-speed transmission of neuronal
signals between distant brain regions, aberrations in white
matter development affects the orchestration of specific cognitive
functions (13, 15). Furthermore, hippocampal alterations have
shown to lead to significant memory deficits, which has been
described as developmental amnesia in this population (37, 38).
In line with this, our group previously found a specific negative
association between the maximum dose of vasoactive medication
received during first admission (measured by the Vasoactive
Inotropic Score; VIS) and long-term verbal and visuospatial
memory in survivors of neonatal ECMO and/or congenital
diaphragmatic hernia. The association was found in both
ECMO and non-ECMO treated patients (9). Although currently
speculative, receiving high levels of vasoactive medication in the
first period of life may be an indirect marker of temporarily
(regional) inadequate brain perfusion. As the hippocampus,
is particularly vulnerable for hypoperfusion and/or hypoxia,
the association between the VIS and memory may be the
indirect result of this pathophysiological mechanism. Future
research in which dense and detailed data on continuous oxygen
saturation and supplemental oxygen supply is combined with
neurodevelopmental outcome is needed to gain further insight
in this potential cause-effect relationship.
Finding ways to protect the brain against hypoxic-ischemic
injury is therefore an important goal for future studies. The use
of pharmacological agents that may have neuroprotective effects
may be of great value in critically ill infants. Dexmedetomidine,
used in particular for sedation in the pediatric ICU population,
may have neuroprotective effects against hypoxic-ischemic
damage (39). These effects have been suggested to result from
an activation of α2-adrenergic receptors by dexmedetomidine,
which inhibits inflammation following brain ischemia (40).
However, these findings are mostly based on animals models and
studies in adult populations (39, 40). Future clinical trials that
assess the efficacy and safety of dexmedetomidine in critically ill
neonates are therefore needed.
FUTURE DIRECTIONS TO IMPROVE
NEURODEVELOPMENT AFTER NEONATAL
CRITICAL ILLNESS
Neurorehabilitation
Given the complex interplay of factors that are likely to affect the
developing brain in critically ill infants, rehabilitation strategies
aimed at improving impaired neuropsychological functions are
of great interest in these patients. Our group has recently
demonstrated short-term gains in verbal working-memory
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and associated increased FA in the left superior longitudinal
fasciculus (SLF) following Cogmed working-memory training
(CWMT) in school-age survivors of neonatal ECMO and/or
CDH (29). These findings are in line with the effects
demonstrated in other clinical and non-clinical groups after
CWMT (8, 41–46). One year after CWMT, neuropsychological
follow-up showed that gains in visuospatial memory delayed
recall persisted long-term (47). Unfortunately, MRI was not
performed at this time, hampering our understanding of the
neurobiological mechanisms that may be underlying these long-
term changes. Nonetheless, as previous findings showed that
over 50% of school-age survivors of neonatal ECMO and/or
CDHhave long-term visuospatial memory deficits (9), improving
memory in these children is of great importance.
Ideally, intervention should take place before memory
problems have interfered with school performance. In children
with very low birth weight, memory improvements have been
found 6 months after CWMT at preschool-age (41), suggesting
earlier intervention may lead to similar results. However,
these results need to be replicated in preschool survivors
of neonatal ECMO and/or CDH with long-term visuospatial
memory deficits, as well as in other survivors of critical
illness such as following complex cardiac anomalies, before
any definitive conclusions can be drawn. In future trials,
neuropsychological assessment and neuroimaging should be
conducted both immediately and 1 year post-intervention.
These studies demonstrate that neurocognition is malleable
with CWMT in survivors of neonatal critical illness. However, it
is not the (complete) answer to the long-term neuropsychological
deficits observed in these children. Results described in this
paper demonstrate that multiple neuropsychological domains
are affected in both survivors of neonatal severe respiratory
failure and complex cardiac anomalies, either treated with or
without ECMO. It is therefore essential to conduct an elaborate
neuropsychological assessment before initiating CWMT in
survivors of neonatal critical illness to determine its clinical
utility. Furthermore, if multiple domains are affected in a child,
treatment strategies should ideally affect multiple domains as
well. A combination of different intervention programs may
therefore be of interest. Findings from both experimental and
clinical studies have suggested that multimodal training leads to
better results compared to a single training program (48, 49).
Exercise training in children has been found to affect memory
and learning by targeting the hippocampus (50). Combining such
a physical program with cognitive training aimed at improving
attention ormemory, may strengthen the results and be beneficial
in survivors of neonatal critical illness. However, these are future
perspectives and of little use in today’s clinical practice.
Currently, survivors of neonatal critical illness with long-
term neuropsychological deficits may have to manage with
practical tools to improve school performance and daily life
activities. To improve long-term neurocognitive outcome in
these children, we recommend that survivors of neonatal critical
illness receive information on the practical implications of
the deficits they may experience (e.g., difficulty remembering
homework that is due tomorrow or appointments with friends),
as well as learn about compensatory techniques or external
(memory) aids that may be used to improve their activities of
daily living [e.g., errorless learning, mental imagery to improve
recall, writing important things down and using a schedule
book (51)]. Ideally, this information is personalized to the
patient’s specific neuropsychological impairments and needs.
Personalized information on neuropsychological deficits and
practical tools can be realized by conducting neuropsychological
assessment to evaluate the degree of neuropsychological deficits,
as well as by evaluating the degree to which these deficits affect
activities of daily living in the patient (51).
For all survivors of neonatal critical respiratory and cardiac
illness, whether treated with or without ECMO, a long-term
follow-up program with regular assessments across development
that covers various medical and neurodevelopmental domains
is recommended. It is important that follow-up continues until
school-age and into adolescence, as these children seem to
“grow into deficit” where early brain damage does not become
functionally evident until cognitive functioning increases later in
life (3). The neuropsychologist as such can play an essential role
in (the improvement of) long-term outcome following neonatal
critical illness (Figure 1). A multidisciplinary approach to long-
term follow-up after neonatal critical illness should therefore
be strived for. Please refer to IJsselstijn et al. (52) for more
detailed recommendations on multidisciplinary age-appropriate
follow-up programs in these patients.
Prevention
Ideally, the deleterious effects of neonatal critical illness on
the neonatal brain should be prevented. This may be (partly)
accomplished by fine-tuning therapy or treatment strategies, but
may also be achieved with the use of neuroprotective agents in
the future. While the specific pathophysiological mechanisms
underlying the neurocognitive deficits are yet to be identified,
we do know that the hippocampus is highly vulnerable in this
population (2). The use of pharmacological agents that may
have neuroprotective effects may therefore be of great value in
FIGURE 1 | The role of the neuropsychologist in multidisciplinary follow-up
after neonatal critical illness.
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critically ill infants. For instance, maternal allopurinol, which
may protect the fetus against hypoxic-ischemic brain injury, is
currently being conducted (53). Here, we mention two other
potentially neuroprotective agents that are already commonly
used in the neonatal intensive care unit (NICU).
Dexmedetomidine, used in particular for sedation in the
pediatric ICU population, may have neuroprotective effects
on the hippocampus, in particular against hypoxic-ischemic
damage (39). These effects have been suggested to result from
an activation of α2-adrenergic receptors by dexmedetomidine,
which inhibits inflammation following brain ischemia (40). As
the hippocampus has been found to be vulnerable to both
hypoxia-ischemia as well as inflammation (2), this specific
mechanisms of action is of interest. However, these findings are
mostly based on animals models and studies in adult populations
(39, 40). Future clinical trials that assess the efficacy and safety of
dexmedetomidine in critically ill neonates are therefore needed
that also include neurobiological outcome parameters, such as
hippocampal volume. Another agent that may be of interest
in this respect is erythropoietin. Erythropoietin is produced by
various cell types in the developing brain as a growth factor
and as an endogenous neuroprotective response to hypoxia (54).
As previously mentioned, in addition to hypoxia, high oxygen
concentrations as a result of supplementary oxygen may lead to
neonatal brain damage as well (34, 55–58). A recent study in
6-day-old rat pups showed that a single dose of erythropoietin
at the onset of hyperoxia (24 h 80% oxygen) improved memory
impairment and reduced acute oligodendrocyte degeneration up
to the adolescent and adult stage (59). Given the vulnerability
of pre-oligodendrocytes in the periventricular white matter
during the perinatal period (35), which may potentially be
(partly) underlying the attention and memory deficits observed
later in life in survivors of neonatal critical illness (9, 11),
reducing microstructural abnormalities in these fibers would
have direct clinical benefits. In addition, studies have found
that erythropoietin may have neurotrophic effects as well by
increasing synaptic plasticity in the hippocampus and improving
memory formation (59, 60).
The hippocampus shows a high degree of neuroplasticity,
which means it has the unique ability to adapt and reorganize
in response to internal or external stimuli (58). Although
this unfortunately seems to result in more pronounced
vulnerability than plasticity—the mechanisms underlying this
(im)balance remaining largely unknown—its ability to generate
new neurons throughout life does make it a promising target
in this respect (58). Trials on potentially neurotrophic agents
such as erythropoietin are therefore of interest. In infants
with extreme prematurity, hypoxic-ischemic encephalopathy,
perinatal stroke, and complex cyanotic heart disease, trials
have demonstrated safety, and the potential for efficacy of
erythropoietin (61). However, the optimal dose and regimen
for neuroprotection in neonates remains largely unknown
(62). Future clinical intervention trials assessing the effects
of neuroprotective agents before, during or after exposure
to both hypoxia and hyperoxia are needed in critically
ill neonates.
CONCLUSIONS
Growing up after severe or cardiac respiratory failure in the
neonatal period comes with an increased risk of neurocognitive
deficits, which seem to be independent of ECMO treatment.
In survivors of cardiac failure, widespread neurodevelopmental
deficits are more often described than in survivors of respiratory
failure, who seem to have more selective neurodevelopmental
deficits in attention and memory. This may be due to the
timing of brain injury, as brain alterations have been found to
exist already in utero in patients with congenital heart disease.
Nonetheless, academic failure has been reported in both groups.
It is therefore of utmost importance that long-term outcome
improves in these patient groups. Future studies are needed
to identify early biomarkers or risk factors to improve early
identification and intervention of children at risk. Furthermore,
neuroprotective strategies should be explored. To improve
outcome following neonatal critical illness in current practice,
psychoeducation, compensatory techniques and external (aids)
should become a standard part of (long-term) care following
neonatal critical illness.
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